Answers are grounded in this paper and cite their sources.
Background & aims Acute-on-chronic liver failure (ACLF) in cirrhotic patients is characterized by severe inflammation, organ failure and high short-term mortality. This proof-of-concept pilot study was aimed at evaluating the effects of plasma exchange (PE) with human serum albumin 5% (PE-A5%) on the albumin functional capacity and organ dysfunction in ACLF patients. Methods Ten adult patients were enrolled in a single-center phase-2, prospective, open-label, non-controlled study. Six PE-A5% were performed in 10 days followed by a one-month follow-up visit. Albumin functional capacity, circulatory, renal, cerebral, liver dysfunction, and systemic inflammation were assessed. Main safety variable was the percentage of PE associated with at least one procedure-related adverse event (AE). Results ACLF patients showed lower albumin binding capacity, lower antioxidant capacity, and lower levels of albumin with preserved structure with respect to healthy donors (n=19). PE-A5% treatment increased albumin levels and improved albumin binding capacity to Sudlow site II (15.3±1.6 mg/mL vs to 18.9±1.7 mg/mL; P =0.003), fatty acid binding capacity (8.2±1.4 μM vs to 3.1±1.5 μM; P =0.013) and antioxidant capacity (HMA 9.5±1.5mg/mL vs to 14.6±1.6 mg/mL; P =0.001). Native albumin levels were increased throughout day 1-11 PE-A5% sessions (6.5±1.0 mg/mL to 10.2±1.4 mg/mL ( P =0.01). PE-A5% improved systemic hemodynamics (mean arterial pressure, heart rate, cardiac index), renal function (creatinine level, blood urea nitrogen), cerebral function (hepatic encephalopathy grade), liver parameters (transaminases, bilirubin) and inflammatory parameters (C-reactive protein, leukocyte count). All patients had at least one of the 78 AEs reported, mostly mild (product/procedure-related: 36%). Sixteen serious AEs were reported in 8 patients (procedure/product-related: none). Conclusions PE-A5% was a safe procedure associated with positive effects on albumin functionality, circulatory, renal, cerebral, and liver functions in cirrhotic patients with ACLF. ClinicalTrials.gov Identifier NCT01201720 EudraCT number 2010-021360-15 Impact and implications Acute-on-chronic liver failure (ACLF) is a clinical condition characterized by severe systemic inflammation, organ failure, and high mortality. Plasma exchange removes patient's plasma containing pathogenic substances, replacing it by 5% albumin and fresh frozen plasma (PE-A5%). In this study, cirrhotic patients with ACLF were treated with PE-A5%, which was a safe procedure that increased binding and antioxidant capacity of patients' albumin, while improving circulatory, kidney, brain, and liver functions. These beneficial effects could impact survival in ACLF.
No takes yet. Share an insight, caveat, or question.
Fernández et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: